Search results
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
Zacks· 3 days agoFree Report) closed the most recent trading day at $78.99, moving +1.24% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.11%. Coming into today, shares of ...
Some drugmakers to cap cost of asthma inhalers at $35 a month
NBC Universal via AOL· 6 days agoStarting Saturday, the cost of inhalers will fall for many Americans, as new out-of-pocket price...
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 6 days agolongest-serving chief executive, Pascal Soriot, has no plans to step down for now as the company...
Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.
The Wall Street Journal· 4 days agoMore patients can fend off the disease for months or years with targeted or immune-boosting drugs,...
AstraZeneca (NASDAQ:AZN) Now Covered by Analysts at The Goldman Sachs Group
ETF DAILY NEWS· 6 days agoThe Goldman Sachs Group assumed coverage on shares of AstraZeneca (NASDAQ:AZN – Free Report) in a research report report published on Thursday morning, Marketbeat Ratings ...
AstraZeneca PLC ADR TradeGate Stock Price Today | NASDAQ AZNPy Live Ticker - Investing.com
Investing.com· 20 hours agoRisk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for ...
New antibiotic based on AstraZeneca drugs kills off deadly bacteria, spares the good guys
FierceBiotech· 6 days agoA new antibiotic based on drugs developed by AstraZeneca can kill off dangerous bacteria that cause...
3 No-Brainer Stocks to Buy in June
Motley Fool via Yahoo Finance· 4 days agoBut what does June bring? Three Motley Fool contributors think the new month should usher in great investing opportunities. Here's why they picked AbbVie...
3 No-Brainer Stocks to Buy in June | The Motley Fool
The Motley Fool· 4 days agoYou're probably familiar with the old adage, "April showers bring May flowers." Here's why they picked AbbVie (ABBV 3.15%), AstraZeneca (AZN 1.63%), and...
Compugen hits milestone with AstraZeneca cancer trial By Investing.com
Investing.com· 7 days agoThe trial is a crucial step in evaluating the drug as a first-line treatment for a specific type of...